{"id":"gsk1024850a-synflorixtm","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Injection site erythema"},{"rate":"5-20%","effect":"Injection site swelling"},{"rate":"10-25%","effect":"Fever"},{"rate":"5-15%","effect":"Irritability"},{"rate":"5-10%","effect":"Drowsiness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains polysaccharide antigens from 13 serotypes of pneumococcus conjugated to a protein carrier, which enhances immunogenicity and promotes both antibody and T-cell mediated immunity. This induces protective antibodies against the targeted pneumococcal strains, reducing the risk of invasive pneumococcal disease and related infections.","oneSentence":"Synflorix is a pneumococcal conjugate vaccine that stimulates immune responses against multiple serotypes of Streptococcus pneumoniae.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:40.866Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease in infants and children"},{"name":"Prevention of pneumococcal otitis media and pneumonia in pediatric populations"}]},"trialDetails":[{"nctId":"NCT00814710","phase":"PHASE3","title":"Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03-07","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae","enrollment":360},{"nctId":"NCT00652951","phase":"PHASE3","title":"Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04-01","conditions":"Infections, Streptococcal","enrollment":780},{"nctId":"NCT01235949","phase":"PHASE4","title":"Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-11-12","conditions":"Infections, Streptococcal","enrollment":850}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"GSK1024850A (SynflorixTM)","genericName":"GSK1024850A (SynflorixTM)","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"GSK1024850A, also known as Synflorix, is a pneumococcal conjugate vaccine used to prevent infections caused by Streptococcus pneumoniae. It is administered as part of a primary vaccination course in healthy children aged 6 to 10 weeks.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}